Policy | December 29, 2025
Govt cancels registration of popular cosmetic product over misleading claims
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
It is the first-ever approval in India for the treatment of Female Pattern Hair Loss (FPHL) and will be available only on prescription by a dermatologist
Subscribe To Our Newsletter & Stay Updated
